MedTrace Logo

Mistletoe Extract in Early or Advanced Breast Cancer, A Feasibility Study

NCT00176046 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2017-05-08

No results posted yet for this study

Summary

The purpose of this feasibility study is to identify appropriate surrogate parameters for a randomized study to examine the efficacy of a complementary therapy with an extract of viscum album (Iscador P) in patients with breast cancer.

Conditions

Interventions

DRUG

viscum album pini

s.c. injection of 0,001-20 mg 3 times per week

DRUG

viscum album pini

s.c. injection 0,001-20 mg 3 times per week

Sponsors & Collaborators

  • Verein für Krebsforschung, Arlesheim, Swizzerland

    collaborator UNKNOWN

  • Weleda AG, D-73525 Schwäbisch Gmünd

    collaborator UNKNOWN

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Cornelia U. von Hagens, MD · Department of Complementary and Integrative Medicine Women's Hospital, University of Heidelberg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-05-31
Primary Completion
2009-06-30
Completion
2009-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00176046 on ClinicalTrials.gov